Abstract:Background: Colorectal cancer (CRC) is one of the most commonly diagnosed and deadly malignant tumors globally, and its occurrence and progression are closely related to the heterogeneity of poor histological features and molecular characteristics among patients.Methods: Comprehensive experiments were performed to validate the role of xCT expression in CRC tumorigenesis and stemness. Bioinformatic analysis and luciferase assays were used to identify upstream transcription factors of SLC7A11. RNA sequencing, Western blotting, and immunofluorescence assays were used to explore the potential mechanisms of xCT in CRC. A rescue assay confirmed the role of MELK in E2F1/xCT-mediated tumorigenesis and stemness in CRC.Results: xCT knockdown significantly suppressed the proliferation, migration and stemness of CRC cells in vitro and effectively inhibited CRC tumorigenesis and metastasis in vivo. E2F1 was identified as a critical upstream transcription factor of xCT that facilitated CRC progression and cell stemness. MELK was confirmed to directly co-expressed with xCT in CRC cells, and its upregulation significantly attenuated xCT knockdown-induced suppression of tumorigenesis and stemness in CRC cells. Further molecular mechanism exploration confirmed that xCT knockdown may exert an antitumor effect by controlling the activation of MELK-mediated Akt/mTOR signaling. Erastin, a specific inhibitor of xCT, was also proven to effectively inhibit CRC tumorigenesis and cell stemness.Conclusion: Altogether, our study showed that E2F1/xCT is a promising therapeutic target of CRC that promotes tumorigenesis and cell stemness. Erastin is also an effective antitumoral agent for CRC.Funding: This study was supported by the National Key Research and Development projects intergovernmental cooperation in science and technology of China (2018YFE0126900), and The Key Research and development Project of Zhejiang Province (No. 2020ZJZC03), The Medical and Health Science and Technology Project of Zhejiang Province (Nos. 2020RC042, 2020KY380 and 2020KY1085).Declaration of Interest: None to declare. Ethical Approval: All experiments involving animals were conducted according to the ethical policies and procedures approved by Experimental Animal Welfare Ethics Review Committee of Zhejiang University, China.

KCTD12 Regulates Colorectal Cancer Cell Stemness Through the ERK Pathway

Endothelial Cells Activate the Cancer Stem Cell-Associated Nanogp8 Pathway in Colorectal Cancer Cells in A Paracrine Fashion

Targeting CDK12 Obviates the Malignant Phenotypes of Colorectal Cancer Through the Wnt/β-catenin Signaling Pathway

The Role of KDM2B and EZH2 in Regulating the Stemness in Colorectal Cancer Through the PI3K/AKT Pathway

Contribution of KCTD12 to esophageal squamous cell carcinoma

Upregulation of CPE promotes cell proliferation and tumorigenicity in colorectal cancer

A pan-cancer analysis of potassium channel tetramerization domain containing 12 in human cancer

A Disintegrin and Metalloproteinase Domain 17 Regulates Colorectal Cancer Stem Cells and Chemosensitivity Via Notch1 Signaling

Downregulation of DAPK1 promotes the stemness of cancer stem cells and EMT process by activating ZEB1 in colorectal cancer

Xct Contributes to Colorectal Cancer Tumorigenesis Through Upregulation of the MELK Oncogene and Activation of the AKT/mTOR Cascade.

KCTD12 Promotes G1/S Transition of Breast Cancer Cell Through Activating the AKT/FOXO1 Signaling

KCNJ14 Knockdown Significantly Inhibited the Proliferation and Migration of Colorectal Cells

Up-regulated CKS2 Promotes Tumor Progression and Predicts a Poor Prognosis in Human Colorectal Cancer.

CDK12 Orchestrates Super‐enhancer‐associated CCDC137 Transcription to Direct Hepatic Metastasis in Colorectal Cancer

KLF12 Interacts with TRIM27 to affect Cisplatin Resistance and Cancer Metastasis in Esophageal Squamous Cell Carcinoma by regulating L1CAM Expression

KCTD9 inhibits the Wnt/β-catenin pathway by decreasing the level of β-catenin in colorectal cancer

Enrichment of Colorectal Cancer Stem Cells Through Epithelial-Mesenchymal Transition Via CDH1 Knockdown.

KCTD12 promotes tumorigenesis by facilitating CDC25B/CDK1/Aurora A-dependent G2/M transition

Cadherin-12 enhances proliferation in colorectal cancer cells and increases progression by promoting EMT

Identifying the E2F3-MEX3A-KLF4 Signaling Axis That Sustains Cancer Cells in Undifferentiated and Proliferative State

E2F1/xCT-Mediated Augmentation of the Oncogene MELK Maintains Colorectal Cancer Cell Stemness and Facilitates Tumorigenesis